卷曲霉素抗结核作用及耐药机制的研究进展  

Advances in research of capreomycin on anti-tuberculosis effect and drug resistance mechanism

作　　者：官政燕 刘梅 陈玲 GUAN Zheng-yan;LIU Mei;CHEN Ling(Department of Respiratory Medicine,The Affiliated Hospital of Zunyi Medical College,Zunyi 563003,China)

机构地区：[1]遵义医科大学附属医院呼吸与危重症医学科结核病区

出　　处：《中国人兽共患病学报》2019年第8期763-768,773,共7页Chinese Journal of Zoonoses

基　　金：国家自然科学基金(No.81760003);贵州省卫生计生委科学技术基金(No.gzwjkj2018-1-024)联合资助~~

摘　　要：卷曲霉素(Capreomycin, CPM)是治疗耐多药结核病的二线注射类药物。随着临床上越来越多的使用,CPM耐药问题正逐步浮现,其作用及耐药机制尚未明确。本文针对卷曲霉素治疗结核病的作用机制、耐药机制及相关基因突变的研究进展进行综述,以供研究者参考。Capreomycin (CPM) is considered to be a key second-line injectable drug in the treatment of multidrug-resistant tuberculosis(MDR-TB). with the increasing use of CPM in clinical practice, the problem of drug resistance of CPM is gradually emerging, and its function and mechanism of drug resistance have not been clarified. In this review, the mechanism of action, drug resistance and related gene mutation of Capreomycin (CPM) in the treatment of tuberculosis are summarized.

关 键 词：卷曲霉素 结核分枝杆菌 作用机制 耐药机制 基因变异 

分 类 号：R378.91[医药卫生—病原生物学] R978.3[医药卫生—基础医学]